Table 1.

Influence of relaxin (or vehicle) administration by subcutaneous osmotic pump on cranial lesion closure

	Lesion Closure (%)		BV(mm3)		BV/TV (%)		BMD (g/cm3)		TMD (g/cm3)
	V	R	V	R	V	R	V	R	V	R
Protocol 1	73.5 ± 3.5	67.0 ± 3.4	0.172 ± 0.012	0.165 ± 0.012	35.3 ± 1.4	34.3 ± 1.8	0.441 ± 0.015	0.428 ± 0.021	0.973 ± 0.007	0.964 ± 0.008
P‐value	0.216		0.709		0.696		0.635		0.424
Protocol 2	54.3 ± 2.2	45.8 ± 3.6	0.128 ± 0.011	0.104 ± 0.010	25.6 ± 0.9	21.9 ± 1.3	0.351 ± 0.009	0.310 ± 0.015	0.942 ± 0.006	0.943 ± 0.005
P‐value	0.072		0.143		0.039		0.039		0.903
Protocol 3	70.3 ± 9.5	76.1 ± 5.1	0.440 ±  0.141	0.457 ± 0.024	28.3 ± 6.0	33.3 ± 2.6	0.371 ± 0.072	0.428 ± 0.025	1.001 ± 0.030	1.002 ± 0.004
P‐value	0.591		0.895		0.444		0.434		0.963

Mean ± SEM. BV, bone volume; BV/TV, bone volume fraction; BMD, bone mineral density; TMD, tissue mineral density; V, vehicle; R, recombinant human relaxin.

Protocol 1: mice were euthanized ~11 weeks after implementing bilateral 1.5 mm cranial lesions and subcutaneous implantation of 14 day osmotic pumps containing recombinant human relaxin (rhRLX; 1.0 μg/h) or vehicle (n = 6 mice each for relaxin and vehicle treatments).

Protocol 2: mice were euthanized 11–12 days after implementing bilateral 1.5 mm cranial lesions and subcutaneous implantation of 14 day osmotic pumps containing recombinant human relaxin (rhRLX; 0.05 μg/h) or vehicle (n = 6 mice each for relaxin and vehicle treatments).

Protocol 3: mice were euthanized ~5 weeks after implementing bilateral 3.0 mm cranial lesions and subcutaneous implantation of 14 day osmotic pumps containing recombinant human relaxin (rhRLX; 0.2 μg/h) or vehicle (n = 4 relaxin and n = 3 vehicle treated mice).